Indeed, compromised PERK-eIF2α phosphorylation significantly extends the population doubling time and results in smaller clone sizes in human K562 CML cells with dominant-negative PERK or eIF2α. This evidence concerns the gene EIF2A and chronic myelogenous leukemia, BCR-ABL1 positive.